Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts

Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only one of its questions is specific to axial symptoms. Alternatively, the Ankylosing Spondylitis Disease Activity Score (ASDAS) excludes assessment of enthesitis, gives less weight to peripheral activity and is considered […]

AB0894 Efficacy and Safety of Guselkumab in Biologic-Naïve Patients With Active Axial Psoriatic Arthritis: Study Design of a Phase 4, Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts

Soumya CHAKRAVARTY, Senior Director & Strategic Lead Rheumatology Therapeutic Area, MD PhD, Immunology Medical Affairs

PDF) Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial

New evidence on the management of spondyloarthritis

Poster Abstract Presentation Abstracts - 2023 - International Journal of Rheumatic Diseases - Wiley Online Library

PDF) Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study

Enrique SORIANO, Head Rheumatology Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Department of Clinical Medicine

PDF) Management of psoriatic arthritis: a consensus opinion by expert rheumatologists

POS1540 EARLY SKIN AND EARLY ENTHESITIS RESPONSES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB ASSOCIATE WITH LONG-TERM RESPONSE: POST HOC ANALYSIS THROUGH 2 YEARS OF A PHASE 3 STUDY

POS0235 COMPARISON OF AXIAL AND PERIPHERAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS IN UPADACITINIB CLINICAL TRIALS

PDF) Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA